13F Holdings
中文EN

PFE PFIZER INC

Pharmaceutical Preparations · NYSE · SEC CIK 78003 · Fiscal year ends 12/31

Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1.3%
TTM net income YoY-59.0%
TTM EPS YoY-59.3%
Revenue 3-yr CAGR-2.8%
Net income 3-yr CAGR-27.3%

Margins

Gross margin73.4%
Operating margin—
Net margin6.3%
FCF margin18.5%
EBITDA margin—

Returns

ROE4.4%
ROA2.0%
ROIC (approx.)—
Asset turnover0.31x

Leverage & solvency

Liabilities / assets56.3%
Debt / equity0.70x
Current ratio1.42x
Interest coverage—

Cash quality & payout

Operating cash flow / net income3.51x
Accruals ratio-4.9%
Payout ratio—
Capex / revenue3.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$62.58B$63.63B$59.55B$101.17B$81.29B
Cost of revenue$16.07B$17.85B$24.95B$34.34B$30.82B
Gross profit$46.51B$45.78B$34.60B$66.83B$50.47B
R&D expense$10.44B$10.82B$10.68B$11.43B$10.36B
SG&A expense$13.79B$14.73B$14.77B$13.68B$12.70B
Interest expense$2.67B$3.09B$2.21B$1.24B$1.29B
Pretax income$7.52B$8.02B$1.06B$34.73B$24.31B
Income tax-$266.00M-$28.00M-$1.11B$3.33B$1.85B
Net income$7.77B$8.03B$2.12B$31.37B$21.98B
EPS (basic)1.371.420.385.593.92
EPS (diluted)1.361.410.375.473.85
Dividends declared per share1.721.691.651.611.57
Weighted avg. shares (diluted)5.71B5.70B5.71B5.73B5.71B
Balance sheet
Cash & equivalents$1.14B$1.11B$2.92B$468.00M$1.98B
Short-term investments$9.18B$10.88B$4.40B$18.74B$22.01B
Receivables$11.87B$11.46B$11.57B$10.95B$11.48B
Inventory$10.65B$10.85B$10.19B$8.98B$9.06B
Current assets$42.90B$50.36B$43.33B$51.26B$59.69B
PP&E, net$19.32B$18.39B$18.94B$16.27B$14.88B
Goodwill$71.26B$68.53B$67.78B$51.38B$49.21B
Intangibles$53.73B$55.41B$64.90B$43.37B$25.15B
Total assets$208.16B$213.40B$226.50B$197.21B$181.48B
Current liabilities$36.98B$42.99B$47.79B$42.14B$42.67B
Short-term debt$3.15B$6.95B$10.35B$2.94B$2.24B
Long-term debt$61.64B$57.41B$61.54B$32.88B$36.20B
Total debt$64.80B$64.35B$71.89B$35.83B$38.44B
Total liabilities$121.39B$124.90B$137.21B$101.29B$104.01B
Shareholders' equity$86.48B$88.20B$89.01B$95.66B$77.20B
Net debt$63.65B$63.24B$68.97B$35.36B$36.45B
Cash flow statement
Operating cash flow$11.70B$12.74B$8.70B$29.27B$32.58B
Capital expenditure$2.63B$2.91B$3.91B$3.24B$2.71B
Free cash flow$9.07B$9.84B$4.79B$26.03B$29.87B
Investing cash flow-$1.35B$2.65B-$32.28B-$15.78B-$22.55B
Financing cash flow-$10.30B-$17.14B$26.07B-$14.83B-$9.82B
Depreciation & amortization$6.59B$7.01B$6.29B$5.06B$5.19B
Stock-based compensation$799.00M$877.00M$525.00M$872.00M$1.18B
Share buybacks—$0$0$2.00B$0

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.